Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=157020&wire=4

SRPTinvestors may also contact Joseph E. Levi, Esq. via email atjlevi@levikorsinsky.comor by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.

WHAT'S NEXT? If you suffered a loss in Sarepta during the relevant time frame, you have until August 25, 2025to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.com

https://c212.net/c/img/favicon.png?sn=NY32686&sd=2025-07-18

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-announces-the-filing-of-a-securities-class-action-on-behalf-of-sarepta-therapeutics-incsrpt-shareholders-302508334.html

SOURCE Levi & Korsinsky, LLP

https://rt.newswire.ca/rt.gif?NewsItemId=NY32686&Transmission_Id=202507180845PR_NEWS_USPR_____NY32686&DateId=20250718

COMTEX_467423106/1005/2025-07-18T08:45:37